Author Correction: Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity (Nature Communications, (2016), 7, 1, (10787), 10.1038/ncomms10787): Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity

Ricardo Sant’Anna, Pablo Gallego, Lei Z. Robinson, Alda Pereira-Henriques, Nelson Ferreira, Francisca Pinheiro, Sebastian Esperante, Irantzu Pallares, Oscar Huertas, Maria Rosário Almeida, Natàlia Reixach, Raul Insa, Adrian Velazquez-Campoy, David Reverter, Núria Reig*, Salvador Ventura*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The original version of this Article contained the following errors: The original version of this Article contained an error in the legend of Fig. 5c, which incorrectly omitted the following: ‘Please note that the same control was published in a previous article65 that reported the results obtained for other inhibitors of L55P-TTR aggregation that were tested in the same dot blot assay.’ This error has been corrected in both the PDF and HTML versions of the Article. The original version of this Article omitted a reference to previouswork in ‘Ferreira,N. et al. Molecular Tweezers Targeting Transthyretin Amyloidosis. Neurotherapeutics 11, 450–461 (2014)’. This has been added as reference 65 in the legend of Fig. 5c, as described above. This error has been corrected in both the PDF and HTML versions of the Article. In addition, the original version of the Supplementary Information associated with this Article contained errors in Supplementary Fig. 8,which showed an incomplete dot blot andwas accompanied by an incomplete legend, which incorrectly read ‘Selected images of the dot blot used in main figure 5c.’ The correct version of the legend states ‘Uncropped blot for results shown in Figure 5c. Several compounds (including tolcapone, tafamidis, EGCGand CLR01)were tested in the same dot blot assay as potential inhibitors of L55P-TTR aggregation, sharing the same controls (no inhibitor) on an acetate cellulose membrane. Figure 5c showed the results obtained for the control, tolcapone and tafamidis, while a previous article showed the results obtained for the control, CLR01 and EGCG: Ferreira, N. et al. Molecular Tweezers Targeting Transthyretin Amyloidosis. Neurotherapeutics 11, 450–461 (2014).’ The HTML has been updated to include a corrected version of the Supplementary Information; the original incorrect version of Supplementary Fig. 8 can be found as Supplementary Information associated with this Correction.

Original languageEnglish
Article number582
JournalNature communications
Volume14
Issue number1
DOIs
Publication statusPublished - 3 Feb 2023

Fingerprint

Dive into the research topics of 'Author Correction: Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity (Nature Communications, (2016), 7, 1, (10787), 10.1038/ncomms10787): Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity'. Together they form a unique fingerprint.

Cite this